SYDNEY, Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, is sponsoring the Endpoints ASCO 22 “Accelerating clinical development in China and the US”. Register here https://asco22.endpts.com/TUESDAY, JUNE 711:00am – 11:45am ET (1:00 – 1:45 local time)Novotech Booth at ASCO #14115 The virtual session will cover the latest on the clinical trial landscape and infrastructure in China and includes Novotech’s DCT partner, Obvio Health, on DCT strategies for patient-centric, oncology study design and execution. According to the Endpoints ASCO session: “China and the US are the world’s largest oncology research destinations, and the
The post Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China appeared first on Pharma Mirror Magazine.
